Monday, June 22, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 216 of 1,261
  1. US 11549125

    Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  2. US 11547718

    Modulators of FOXP3 expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  3. US 11547639

    Dental composition containing platinum nanoparticles

    KURARAY NORITAKE DENTAL INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  4. US 11549113

    Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  5. US 11548944

    Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  6. US 11547687

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  7. US 11547683

    Therapeutic compounds, formulations, and uses thereof

    Tvardi Therapeutics, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  8. US 11549112

    RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  9. US 11548899

    Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  10. US 11547670

    Delayed release methylphenidate compositions

    Amneal Complex Products Research LLC · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  11. US 11548852

    Modified amino acids

    Sutro Biopharma, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  12. US 11549950

    Cryptic metabolites and method for activating silent biosynthetic gene clusters in diverse microorganisms

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  13. US 11549109

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  14. US 11548953

    Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof

    The Regents of the University of California · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  15. US 11549147

    Treatment of atopic dermatitis with tradipitant

    VANDA PHARMACEUTICALS INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  16. US 11548932

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  17. US 11548945

    T-cell receptor (TCR)-binding antibodies and uses thereof

    The Board of Regents of the University of Texas System · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  18. US 11548947

    Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  19. US 11548951

    Compositions and methods for treatment of thyroid eye disease

    Viridian Therapeutics, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  20. US 11548940

    Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  21. US 11547759

    Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

    Montelino Therapeutics Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  22. US 11547736

    Sauvignon blanc grape seed products for nonalcoholic fatty liver disease

    The United States of America, as represented by the Secretary of Agriculture · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  23. US 11548889

    Emetine auristatin compounds

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  24. US 11547674

    Protein-polymer hybrid biomaterials

    The Regents of the University of California · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.